Interventions to Slow Aging in Humans: Are We Ready?

View/ Open
Author
Longo, Valter D
Antebi, Adam
Bartke, Andrzej
Barzilai, Nir
Brown-Borg, Holly M
Caruso, Calogero
Curiel, Tyler J
de Cabo, Rafael
Franceschi, Claudio
Gems, David
Ingram, Donald K
Johnson, Thomas E
Kennedy, Brian K
Kenyon, Cynthia
Klein, Samuel
Kopchick, John J
Lepperdinger, Guenter
Madeo, Frank
Mirisola, Mario G
Passarino, Giuseppe
Rudolph, Karl L
Sedivy, John M
Shadel, Gerald S
Spindler, Stephen R
Suh, Yousin
Vijg, Jan
Vinciguerra, Manlio
Fontana, Luigi
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1111/acel.12338Metadata
Show full item recordCitation
Longo, V. D., A. Antebi, A. Bartke, N. Barzilai, H. M. Brown-Borg, C. Caruso, T. J. Curiel, et al. 2015. “Interventions to Slow Aging in Humans: Are We Ready?” Aging Cell 14 (4): 497-510. doi:10.1111/acel.12338. http://dx.doi.org/10.1111/acel.12338.Abstract
The workshop entitled ‘Interventions to Slow Aging in Humans: Are We Ready?’ was held in Erice, Italy, on October 8–13, 2013, to bring together leading experts in the biology and genetics of aging and obtain a consensus related to the discovery and development of safe interventions to slow aging and increase healthy lifespan in humans. There was consensus that there is sufficient evidence that aging interventions will delay and prevent disease onset for many chronic conditions of adult and old age. Essential pathways have been identified, and behavioral, dietary, and pharmacologic approaches have emerged. Although many gene targets and drugs were discussed and there was not complete consensus about all interventions, the participants selected a subset of the most promising strategies that could be tested in humans for their effects on healthspan. These were: (i) dietary interventions mimicking chronic dietary restriction (periodic fasting mimicking diets, protein restriction, etc.); (ii) drugs that inhibit the growth hormone/IGF-I axis; (iii) drugs that inhibit the mTOR–S6K pathway; or (iv) drugs that activate AMPK or specific sirtuins. These choices were based in part on consistent evidence for the pro-longevity effects and ability of these interventions to prevent or delay multiple age-related diseases and improve healthspan in simple model organisms and rodents and their potential to be safe and effective in extending human healthspan. The authors of this manuscript were speakers and discussants invited to the workshop. The following summary highlights the major points addressed and the conclusions of the meeting.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531065/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:21459232
Collections
- HMS Scholarly Articles [17714]
- SPH Scholarly Articles [6329]
Contact administrator regarding this item (to report mistakes or request changes)